Rethinking developmental toxicity testing: Evolution or revolution?

被引:36
作者
Scialli, Anthony R. [1 ,2 ]
Daston, George [3 ]
Chen, Connie [4 ]
Coder, Praegati S. [5 ]
Euling, Susan Y. [6 ]
Foreman, Jennifer [7 ]
Hoberman, Alan M. [8 ]
Hui, Julia [9 ]
Knudsen, Thomas [10 ]
Makris, Susan L. [11 ]
Morford, LaRonda [12 ]
Piersma, Aldert H. [13 ,14 ]
Stanislaus, Dinesh [15 ]
Thompson, Kary E. [16 ]
机构
[1] Reprod Toxicol Ctr, Washington, DC USA
[2] Scialli Consulting LLC, 2737 Devonshire Pl NW 120, Washington, DC 20008 USA
[3] Proctor & Gamble, Mason, OH USA
[4] ILSI Hlth & Environm Sci Inst, Washington, DC USA
[5] Charles River Labs, Ashland, OH USA
[6] US EPA, Off Childrens Hlth Protect, Washington, DC 20460 USA
[7] ExxonMobil Biomed Sci Inc, Annandale, NJ USA
[8] Charles River Labs, Horsham, PA USA
[9] Celgene Corp, Summit, NJ USA
[10] US EPA, Natl Ctr Computat Toxicol, Res Triangle Pk, NC 27711 USA
[11] US EPA, Natl Ctr Environm Assessment, Washington, DC 20460 USA
[12] Lilly Res Labs, Indianapolis, IN USA
[13] Natl Inst Publ Hlth & Environm RIVM, Ctr Hlth Protect, Bilthoven, Netherlands
[14] Univ Utrecht, Inst Risk Assessment Sci, Utrecht, Netherlands
[15] GlaxoSmithKline, King Of Prussia, PA USA
[16] Bristol Myers Squibb, Drug Safety Evaluat, New Brunswick, NJ USA
关键词
adverse outcome pathways; developmental toxicity testing; embryo-fetal toxicity testing; hypothesis-based testing; Segment II; virtual embryo; ADVERSE OUTCOME PATHWAYS; TOXICOLOGICAL CONCERN; THRESHOLD; CHEMICALS; MODELS; RATS; TTC;
D O I
10.1002/bdr2.1212
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
BackgroundCurrent developmental toxicity testing adheres largely to protocols suggested in 1966 involving the administration of test compound to pregnant laboratory animals. After more than 50 years of embryo-fetal development testing, are we ready to consider a different approach to human developmental toxicity testing? MethodsA workshop was held under the auspices of the Developmental and Reproductive Toxicology Technical Committee of the ILSI Health and Environmental Sciences Institute to consider how we might design developmental toxicity testing if we started over with 21st century knowledge and techniques (revolution). We first consider what changes to the current protocols might be recommended to make them more predictive for human risk (evolution). ResultsThe evolutionary approach includes modifications of existing protocols and can include humanized models, disease models, more accurate assessment and testing of metabolites, and informed approaches to dose selection. The revolution could start with hypothesis-driven testing where we take what we know about a compound or close analog and answer specific questions using targeted experimental techniques rather than a one-protocol-fits-all approach. Central to the idea of hypothesis-driven testing is the concept that testing can be done at the level of mode of action. It might be feasible to identify a small number of key events at a molecular or cellular level that predict an adverse outcome and for which testing could be performed in vitro or in silico or, rarely, using limited in vivo models. Techniques for evaluating these key events exist today or are in development. DiscussionOpportunities exist for refining and then replacing current developmental toxicity testing protocols using techniques that have already been developed or are within reach.
引用
收藏
页码:840 / 850
页数:11
相关论文
共 42 条
[1]  
[Anonymous], 2017, READ ACR ASS FRAM
[2]   Reproductive and developmental toxicology studies with gantenerumab in PS2APP transgenic mice [J].
Barrow, Paul ;
Villabruna, Loris ;
Hoberman, Alan ;
Bohrmann, Bernd ;
Richter, Wolfgang F. ;
Schubert, Christine .
REPRODUCTIVE TOXICOLOGY, 2017, 73 :362-371
[3]   Point of departure (PoD) selection for the derivation of acceptable daily exposures (ADEs) for active pharmaceutical ingredients (APIs) [J].
Bercu, Joel P. ;
Morinello, Eric J. ;
Sehner, Claudia ;
Shipp, Bryan K. ;
Weideman, Patricia A. .
REGULATORY TOXICOLOGY AND PHARMACOLOGY, 2016, 79 :S48-S56
[4]   ILSI/HESI Maternal Toxicity Workshop Summary: Maternal Toxicity and Its Impact on Study Design and Data Interpretation [J].
Beyer, Bruce K. ;
Chernoff, Neil ;
Danielsson, Bengt R. ;
Davis-Bruno, Karen ;
Harrouk, Wafa ;
Hood, Ronald D. ;
Janer, Gemma ;
Liminga, Ulla Wandel ;
Kim, James H. ;
Rocca, Meredith ;
Rogers, John ;
Scialli, Anthony R. .
BIRTH DEFECTS RESEARCH PART B-DEVELOPMENTAL AND REPRODUCTIVE TOXICOLOGY, 2011, 92 (01) :36-51
[5]   Application of Adverse Outcome Pathways to US EPA's Endocrine Disruptor Screening Program [J].
Browne, Patience ;
Noyes, Pamela D. ;
Casey, Warren M. ;
Dix, David J. .
ENVIRONMENTAL HEALTH PERSPECTIVES, 2017, 125 (09)
[6]   Screening Chemicals for Estrogen Receptor Bioactivity Using a Computational Model [J].
Browne, Patience ;
Judson, Richard S. ;
Casey, Warren M. ;
Kleinstreuer, Nicole C. ;
Thomas, Russell S. .
ENVIRONMENTAL SCIENCE & TECHNOLOGY, 2015, 49 (14) :8804-8814
[7]   Probabilistic assessment method of the non-monotonic dose-responses-Part I: Methodological approach [J].
Chevillotte, Gregoire ;
Bernard, Audrey ;
Varret, Clemence ;
Ballet, Pascal ;
Bodin, Laurent ;
Roudot, Alain-Claude .
FOOD AND CHEMICAL TOXICOLOGY, 2017, 106 :376-385
[8]   SEURAT: Safety Evaluation Ultimately Replacing Animal Testing-Recommendations for future research in the field of predictive toxicology [J].
Daston, George ;
Knight, Derek J. ;
Schwarz, Michael ;
Gocht, Tilman ;
Thomas, Russell S. ;
Mahony, Catherine ;
Whelan, Maurice .
ARCHIVES OF TOXICOLOGY, 2015, 89 (01) :15-23
[9]   Predicting Developmental Toxicity Through Toxicogenomics [J].
Daston, George P. ;
Naciff, Jorge M. .
BIRTH DEFECTS RESEARCH PART C-EMBRYO TODAY-REVIEWS, 2010, 90 (02) :110-117
[10]   Grouping 34 Chemicals Based on Mode of Action Using Connectivity Mapping [J].
De Abrew, K. Nadira ;
Kainkaryam, Raghunandan M. ;
Shan, Yuqing K. ;
Overmann, Gary J. ;
Settivari, Raja S. ;
Wang, Xiaohong ;
Xu, Jun ;
Adams, Rachel L. ;
Tiesman, Jay P. ;
Carney, Edward W. ;
Naciff, Jorge M. ;
Daston, George P. .
TOXICOLOGICAL SCIENCES, 2016, 151 (02) :447-461